Beyond maximum grade: a decade in the making The Lancet Haematology +... ++

Beyond maximum grade: a decade in the making The Lancet Haematology https://www.thelancet.com/journals/lanhae/issue/vol13no9/PIIS2352-3026(26)X2008-7 Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial Prof Jeremy S Abramson, MDa Send email to jabramson@mgh.harvard.edu ∙ Prof Susan Geyer, PhDb,c ∙ Sharmila Girib,c ∙ Levi Pedersonb,c ∙ Ann Hudsonb,c ∙ Prof Eric D Hsi, MDd ∙ et al. https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00191-2/abstract?dgcid=raven_jbs_etoc_feature_lanhae Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial Lorenzo Falchi, MDa Send email to falchil@mskcc.org ∙ Joost S P Vermaat, MDb ∙ Joshua D Brody, MDc ∙ Lori Leslie, MDd ∙ Prof Fritz Offner, MDe ∙ Jacob Haaber Christensen, MDf ∙ et al. https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00198-5/fulltext?dgcid=raven_jbs_etoc_feature_lanhae